Redeye states its view on Hoylu’s Q2 2023 report, announced earlier today.
Redeye comments on Remedys Q2-report. Revenue was somewhat below our estimates while EBIT was clearl...
Redeye comments on Coala Life’s Q2’23 report, noting stable sales progress driven mainly by increase...
Aspo’s outlook worsened this spring, and Q2 results fell below reduced estimates.
Carlsquare Equity Research sammanfattar sina första intryck av H&D Wireless kv2 2023-rapport.
Etteplan reported Q2 results that were below our estimates.
Redeye retains its positive view of Efecte following a Q2 report in line with our expectations.
Redeye updates on G5 following its Q2-results where topline was soft while results were close to our...
Done at EUR 146m (book value EUR 163m)Net LTV down to ~27% (~52% as of Q2'23)P/CEPS of ~17.
Sales and adj. EBIT a tad weaker, but FCF strongerWe cut EBIT but raise FCF on lower capexShare trad...
Q2 2023 net sales and operating profit were slightly below our expectations but the deepest decline,...
Q2 adjusted EBITA fell slightly short of Refinitiv consensus expectations despite solid top-line gro...
We expect a Q2 that is largely a continuation of Q1.
Redeye maintains its positive view on Transtema despite lowering its Base Case and forecasts.
Redeye states that the Q2 report was on the weaker side, once again, especially from the products bu...
Low H1 revenue, but progress behind the scenesTarget: SEK 1bn company by 2030, with 25% recurring re...
Redeye comments on Jondetech’s Q2 report, in which positive signs for revenue generation and cash fl...
Carlsquare Equity Research kommenterar förväntingarna inför Spotlight Groups kv2-rapport den 14 augu...
Redeye comments on QleanAir’s Q2 figures where sales were significantly higher than expected, postin...
Relais reported Q2 adjusted EBITA of EUR 4.8m, 3% below Refinitiv consensus and 13% below our estima...
